

INTRODUCTION

Preclinical to Clinical Translation Gap in Alzheimer’s Therapy Development

Positive findings of therapeutics and interventions from studies conducted in Alzheimer’s disease (AD) animal models are often not translated to effective treatments. As comprehensively reviewed by [Zahs and Ashe, 2010](#), more than 200 interventions have been reported to be efficacious in ameliorating pathology and cognitive deficits in transgenic AD animal models, yet none have proven effective in human trials. Detailed analyses of AD clinical trials of candidate drugs considered safe and effective, based on successful preclinical animal studies conducted between 1998 and 2014, were performed by [Cummings et al., 2014](#) and [PhRMA, 2015](#) and reported a very high attrition rate of more than 99%. During this period 244 candidate therapeutics were tested in 413 clinical trials (phases I-III) and only one received FDA approval as a disease-modifying therapeutic – [memantine](#). Systematic reviews and meta-analyses of preclinical animal studies in AD highlight the lack of methodological rigor and inadequate reporting practices as contributive to the preclinical to clinical translation gap in AD therapy development ([Shineman et al., 2011](#), [Landis et al., 2012](#), [Snyder et al., 2016](#), [Percie du Sert et al., 2020](#)).

To combat the challenges presented by the poor translation of AD animal research to effective treatments, the National Institute on Aging (NIA) has convened a number of AD research summits ([2012](#), [2015](#), [2018](#), [2021](#)) aimed at identifying and addressing critical knowledge gaps and proposing ways to utilize emerging technologies to accelerate treatments and preventative strategies for people at all stages of the disease. These summits have brought together leading experts on AD from academia, industry, non-profit organizations, and advocacy groups to develop research priorities and strategies needed to accelerate the development of successful therapies for AD. Also identified during these summits were infrastructure and partnerships necessary to increase the likelihood that preclinical therapeutic development efforts for AD will translate to success in the clinic.

The AD research summits delivered recommendations that served as the foundation for developing the [AD/ADRD Research Implementation Milestones](#). These milestones encompass the entire AD research landscape including basic, translational, clinical and health services research and detail specific measures and success criteria towards the development of effective treatments for AD. One such milestone ([4.B](#) in particular) tasked the NIA to create infrastructure and resources for the development of standardized and rigorous methods for preclinical efficacy testing, including web-based resources for transparent reporting of both positive and negative findings. Specifically, the milestone recommended the development of a publicly available database that housed experimental design and analyses relating to preclinical testing of candidate therapeutic agents in AD animal models and identified critical experimental design elements and methodology that impact rigor and reproducibility of published studies.

AlzPED: Mission, Scope, and Capabilities

Launched in 2016 by the NIA and the NIH Library, the Alzheimer’s Disease Preclinical Efficacy Database ([AlzPED](#)) incorporates all of these recommendations and is a key component of NIA’s new translational infrastructure for AD/ADRD research. AlzPED is a searchable, publicly available knowledgebase hosting curated summaries from nearly 1300 published animal model studies testing candidate therapeutics in AD, aiming to illuminate key elements of experimental design and reporting practices of preclinical efficacy testing studies for researchers, funding agencies, and the public. These curated summaries include information about AD animal models, therapeutic agents, therapeutic targets, outcome measures, related clinical trials, patents, and study design.

FROM MOUSE TO MEDICINE: OPTIMIZING THE PREDICTIVE VALUE OF PRECLINICAL RESEARCH

The database is missioned to improve transparency in reporting, increase awareness of the need for greater rigor in study design, and identify critical experimental design elements and methodology missing from studies that make them susceptible to over-interpretation and reduce their reproducibility and translational value. Through these capabilities, AlzPED is intended to guide the development and implementation of strategies and recommendations for standardized best practices to achieve rigorous preclinical testing of AD candidate therapeutics.

METHODS

Article Selection

AlzPED provides platforms for the submission of both published as well as unpublished studies testing candidate therapeutics in AD animal models, particularly unpublished studies that describe negative results. Published studies are collected from databases like [PubMed](#) and [Embase](#) using key word search strings specific to preclinical therapeutic testing in AD animal models. Unpublished studies, particularly those describing negative results, will be obtained directly from researchers testing candidate therapeutic agents in AD animal models. Efforts to procure these data are continuous and ongoing.

Article Curation

Prior to publication in the database, each study is meticulously curated by 2 experts in AD research for bibliographic details, funding source, study goals and principal findings, data on relevant translational criteria like therapy type, therapeutic agent, therapeutic target, animal models, and AD-related outcome measures. Studies are also assessed for scientific rigor using a “Rigor Report Card” (Figure 1) which identifies the experimental design elements which were reported as well as those missing from the study. Each curated study provides additional relevant information about therapeutic targets, therapeutic agents, and animal models through freely accessible external databases. These databases include [Open Targets](#), [Pharos](#), and [Agora](#), which provide comprehensive and integrated insight into potential therapeutic targets for AD; databases like [PubChem](#) and [DrugBank](#) which describe molecular, chemical, structural and other identifiers for the therapeutic agents being tested; information on clinical trials and patents associated with the therapeutic agent is gleaned from [ClinicalTrials.gov](#) and [Google Patents](#); and finally, [Alzforum](#) provides detailed descriptions of the animal models used.

Data Analysis and Statistics

All data in the database are publicly available and downloadable from the AlzPED “[Search Results](#)” page. Data were analyzed across the translational research criteria of therapy type, therapeutic agent, animal models, and outcome measures. Data are presented as percentages derived from the totality of studies curated in AlzPED. Scientific rigor in study design and methodology was evaluated using the Rigor Report Card consisting of a standardized set of 24 experimental design elements (Figure 1) and results are presented as percentage of studies reporting each of the 24 experimental design elements (Figure 2). Of these 24, 9 core study design elements have been identified as critical for ensuring rigor and reproducibility (Figure 3). Reporting trends in the 9 critical core experimental design elements were evaluated over 5-year spans from 2000 to 2021. Results are presented as “number of studies that reported” vs “number of studies that did not report” the core experimental design elements and analyzed using Chi square tests (Figures 4 & 5). Comparisons of reporting trends in the 9 core experimental design elements between NIH-funded and non-NIH funded studies are assessed using Pearson Chi square and Fisher exact tests and expressed as percentages (Figures 6 & 7).

FROM MOUSE TO MEDICINE: OPTIMIZING THE PREDICTIVE VALUE OF PRECLINICAL RESEARCH

Reporting trends in the experimental design elements were also evaluated based on the impact factor of the journal in which the curated preclinical study is published as well as relative number of citations per year for the study. Current journal impact factors were obtained from [Journal Citation Reports](#). Curated studies were categorized into 4 groups based on current journal impact factor values. Group 1 includes studies published in journals with impact factors below 3, and those published in journals with impact factors between 3 and 4.99, or between 5 and 9.99 are sorted in Groups 2 and 3 respectively. Studies published in high impact journals with impact factors greater than 10 are included in Group 4 (Figure 8). The number of citations for each curated study was obtained from [iCite](#). iCite is a tool to access a dashboard of bibliometrics for published scientific papers developed by the [Office of Portfolio Analysis](#) at the NIH. Relative number of citations for each curated study was calculated by dividing the total number of citations for that study by the number of years since publication. For example, for a study published in 2018, the total number of citations for that study was divided by 3, or for a study published in 2017, the total number of citations for that study was divided by 4, and so on. These studies were categorized into 3 groups based on the relative number of citations per year. Curated studies with less than 3 relative number of citations per year are sorted into Group 1, those with relative number of citations per year between 3 and 7 or those with relative number of citations per year greater than 7 are sorted into Groups 2 and 3 respectively. Data are expressed as Mean \pm SEM and assessed for significance using unpaired t tests (Figure 9).

RESULTS

This growing knowledge platform currently houses 1298 preclinical efficacy studies published between 1996 and the present (Table 1). Efforts are underway to expand the database further and balance the number of studies curated based on the year of publication.

YEAR	# OF PAPERS CURATED	YEAR	# OF PAPERS CURATED	YEAR	# OF PAPERS CURATED
1996	1	2009	56	2020	84
1999	1	2010	62	2021	73
2000	15	2011	63		
2001	19	2012	64		
2002	27	2013	73		
2003	33	2014	73		
2004	58	2015	76		
2005	53	2016	71		
2006	51	2017	84		
2007	50	2018	78		
2008	50	2019	82		

Table 1: The table shows the number of preclinical efficacy studies collected, curated and available in the database and the year of publication. The database currently houses curated summaries from 1298 published studies.

Experimental Design Elements

AlzPED’s Rigor Report Card (Figure 1) provides a standardized set of 24 study design elements that are specifically tailored for rigorous preclinical testing of candidate therapeutics in AD animal models. The Rigor Report Card further defines a succinct set of 9 core design elements that are critical for scientific rigor and reproducibility, without which the reliability of results cannot be assessed (Figure 3). These include design elements that report on power calculation and sample size, blinding for treatment allocation as well as analysis of outcome measures, random allocation of intervention, age, sex, and genetic background of the animal model used, and whether the study has been balanced for sex. Also included are eligibility criteria like inclusion and exclusion criteria that define which animals are eligible to be enrolled in the study, premature deaths and drop-outs, and inclusion of author conflict of interest statement. Further, design elements that characterize the therapeutic agent being tested such as pharmacokinetic, pharmacodynamic, ADME and toxicology measures, dose, and formulation of the therapeutic agent as well as treatment paradigms such as route, frequency and duration of administration, and plan for statistical analysis of study results are also included. These are all common elements of clinical trial study design ([van der Worp et al., 2010](#), [Shineman et al., 2011](#), [Landis et al., 2012](#), [Snyder et al., 2016](#), [Percie du Sert et al., 2020](#)). The [ARRIVE guidelines](#) provide clear definitions and examples for each study design element.

Is the following information reported in the study?



<input type="checkbox"/> Power/Sample Size Calculation ?	<input type="checkbox"/> Randomized into Groups ?
<input type="checkbox"/> Blinded for Treatment ?	<input type="checkbox"/> Blinded for Outcome Measures ?
<input type="checkbox"/> Pharmacokinetic Measures ?	<input type="checkbox"/> Pharmacodynamic Measures ?
<input type="checkbox"/> Toxicology Measures ?	<input type="checkbox"/> ADME Measures ?
<input type="checkbox"/> Biomarkers ?	<input type="checkbox"/> Dose ?
<input type="checkbox"/> Formulation ?	<input type="checkbox"/> Route of Delivery ?
<input type="checkbox"/> Duration of Treatment ?	<input type="checkbox"/> Frequency of Administration ?
<input type="checkbox"/> Age of Animal at the Beginning of Treatment ?	<input type="checkbox"/> Age of Animal at the End of Treatment ?
<input type="checkbox"/> Sex as a Biological Variable	<input type="checkbox"/> Study Balanced for Sex as a Biological Variable
<input type="checkbox"/> Number of Premature Deaths ?	<input type="checkbox"/> Number of Excluded Animals ?
<input type="checkbox"/> Statistical Plan	<input type="checkbox"/> Genetic Background
<input type="checkbox"/> Inclusion/Exclusion Criteria Included ?	<input type="checkbox"/> Conflict of Interest ?

Figure 1: AlzPED is designed to monitor the scientific rigor of curated studies with a “Rigor Report Card” consisting of a standardized set of 24 experimental design elements recommended by expert advisory groups for preclinical therapeutic studies in animals.

Scientific rigor of each curated study is monitored using AlzPED’s Rigor Report Card, which identifies experimental design elements reported in a study as well as those missing from the study. Evaluation of these rigor report cards demonstrate considerable disparities in reporting the 24 experimental design elements (Figure 2). Design elements like dose and formulation of the therapeutic agent being examined, treatment paradigms like route, frequency and duration of administration, age of the animals used in the study, and plan for statistical analysis of study results are consistently reported by at least 95% of the nearly 1300 curated studies. However, critical elements of methodology like power calculation, blinding for treatment allocation, as well as analysis of outcome measures, random allocation of intervention, inclusion and exclusion criteria, and whether the study has been balanced for


FROM MOUSE TO MEDICINE: OPTIMIZING THE PREDICTIVE VALUE OF PRECLINICAL RESEARCH

sex are significantly under-reported, being reported by fewer than 35% of the nearly 1300 curated studies (Figure 3).



FROM MOUSE TO MEDICINE: OPTIMIZING THE PREDICTIVE VALUE OF PRECLINICAL RESEARCH


Reporting trends for the 9 critical core experimental design elements were evaluated over 5-year spans from 2000 to 2021 (Figure 4). Our analysis demonstrates an incremental improvement over consecutive 5-year spans in the proportion of studies reporting several critical elements like blinding for outcome analysis, randomized allocation of therapeutic agent, genetic background as well as sex of the animal model used in the study, and author conflict of interest statement. However, there is little improvement in the proportion of studies reporting power calculation, blinding for treatment allocation, inclusion and exclusion criteria, and whether the study has been balanced for sex. Of note, NIH-issued 2 rigor-related policies – (i) [NOT-OD-11-109](#) issued in 2011 requires transparency in reporting financial conflicts of



FROM MOUSE TO MEDICINE: OPTIMIZING THE PREDICTIVE VALUE OF PRECLINICAL RESEARCH


interest, and (ii) [NOT-OD-15-102](#) was issued in 2015 to emphasize the consideration of sex as a biological variable. Enforcement of these policies clearly improved the reporting of these core experimental design elements.

Further evaluation of the reporting trends in the 9 critical core experimental design elements demonstrates that few studies report more than 5 core design elements, most studies reporting only 2-4 core design elements (Figure 5, top). However, studies published between 2017 and 2021 report between 3-5 core design elements compared with those published between 2000 and 2006 which report 1-2 core design elements (Figure 5, bottom).



FROM MOUSE TO MEDICINE: OPTIMIZING THE PREDICTIVE VALUE OF PRECLINICAL RESEARCH

NIH-issued [policies](#) to [enhance the rigor, reproducibility and translatability](#) of research place significant emphasis on rigorous scientific method, study design, and consideration of biological variables such as sex. Analysis of study design and methodology of NIH-funded published studies curated in AlzPED demonstrates a positive impact of these policies. NIH-funded studies show significantly improved reporting of power/sample size calculation, blinding for outcome measures, inclusion/exclusion criteria and balancing the study for sex (Figure 6). Non-NIH funded studies include those funded by US federal and state organizations, nonprofit organizations, pharmaceutical companies, the European Union, non-EU European governments, governments of Canada, Mexico, Brazil, China, Japan, South Korea, India, Iran, Australia and others, and University start-ups.



Studies funded exclusively by the NIH show significantly improved reporting of inclusion/exclusion criteria and balancing the study for sex (Figure 7) compared with those supported by specific non-NIH funding sources that include the European Union, nonprofit organizations, pharmaceutical companies, governments of China and other south and east Asian countries (Japan, South Korea, India, Hong Kong and Taiwan).

FROM MOUSE TO MEDICINE: OPTIMIZING THE PREDICTIVE VALUE OF PRECLINICAL RESEARCH





Figure 7: Comparison of reporting trends in 9 core experimental design elements between NIH-funded and non-NIH funded studies. Data are presented as percentages calculated from 115 (exclusively) NIH-funded studies, 47 studies funded by the European Union, 59 pharmaceutical industry-funded studies, 48 studies funded by private foundations, 62 studies funded by south and east Asian governments and 150 studies funded by the Chinese government. Studies included in the south and east Asian government funding category were funded by Japanese, South Korean, Indian, Taiwanese and Hong Kong governments. Data are analyzed using the Pearson Chi square test, * $p < 0.05$ and ** $p < 0.001$ presented as percentage reported.


The lack of rigor and reproducibility of research findings in the scientific publishing arena is [well documented](#). A [systematic review](#) of the rigor and translatability of highly cited animal studies published in leading scientific journals (including Science, Nature, Cell, and others) demonstrated a lack of scientific rigor in study design. A comprehensive review of reporting trends for critical experimental design elements in highly cited studies published in leading journals that are curated in AlzPED revealed a similar pattern of poor study design and reporting practices. These analyses are described in greater detail in the next segment.

Reporting trends for the 9 core and all 24 experimental design elements were evaluated based on the impact factor of the journal in which the curated preclinical study was published (Figure 8). These studies were categorized into 4 groups based on 2021 journal impact factor values. Curated studies published in journals with impact factors below 3 were sorted in Group 1, and those published in journals with impact factors between 3 and 4.99, or between 5 and 9.99 were sorted in Groups 2 and 3 respectively. Studies published in high impact journals with impact factors greater than 10 were sorted in Group 4. While t-tests show that there are statistically significant differences in reporting the 9 core elements as well as all 24 elements of experimental design between these four groups, overall, the data demonstrate poor reporting practices irrespective of journal impact factor.

FROM MOUSE TO MEDICINE: OPTIMIZING THE PREDICTIVE VALUE OF PRECLINICAL RESEARCH



Reporting trends for the 9 core and all 24 experimental design elements were evaluated based on the relative number of citations per year of each curated study published between 1996 and 2021 (Figure 9). Relative number of citations for each curated study was calculated by dividing the total number of citations for that study by the number of years since publication. For example, for a study published in 2020, the total number of citations for that study was divided by 2, or for a study published in 2019, the total number of citations for that study was divided by 3, and so on. These studies were categorized into 3 groups based on the relative number of citations per year. Curated studies with less than 3 relative number of citations per year were sorted into Group 1, those with relative number of citations per year between 3 and 7 or those with relative number of citations per year greater than 7 were sorted into Groups 2 and 3 respectively. While t-tests show that there are statistically significant differences in reporting the 9 core elements as well as all 24 elements of experimental design between these three groups, overall, the data demonstrate poor reporting practices irrespective of relative number of citations per year.



FROM MOUSE TO MEDICINE: OPTIMIZING THE PREDICTIVE VALUE OF PRECLINICAL RESEARCH

Cumulatively, these data demonstrate the serious deficiencies in reporting critical elements of study design and methodology in the nearly 1300 curated studies analyzed, even those published in high impact factor journals as well those that are highly cited. These deficiencies diminish the scientific rigor, reproducibility, and predictive value of preclinical therapeutic studies done in AD animal models. In light of these results, adoption and implementation of a standardized set of best practices and study design guidelines will very likely improve the predictive validity of preclinical therapeutic studies done in AD animal models. This measure will likely promote the effective translation of preclinical candidate therapeutic testing to the clinic. To this end, several [meetings](#) and [workshops](#) have been held between the NIH and journal publishers to discuss issues of increasing reproducibility, improving rigor of research findings, identifying common opportunities to enhance rigor in study design, and supporting research that is reproducible and transparent. For example, notice [NOT-OD-11-09](#) issued by the NIH in 2011 requires transparency in reporting financial conflicts of interest. Similarly, most publishers now require investigators to report financial conflicts of interest. Enforcement of these requirements clearly improved reporting this design element. It is therefore imperative that the NIH, other federal funding agencies, private foundations and scientific journal publishers require investigators to follow these accepted best practices and study design guidelines to ensure that funded as well as published research are sufficiently rigorous, transparent, and reproducible.

Therapeutics

A diverse array of therapeutic agents and targets are reported in the 1298 studies curated in AlzPED. The database catalogues 1123 novel therapeutic agents into 16 distinct categories (Figure 10) based on agent source (natural product or synthetic), molecular structure (biologic or small molecule), chemical nature (peptide, nucleic acid, or hormone) and mechanism of action (immunotherapy – active or passive).





Figure 10: The graph shows the diverse types of therapeutic agents tested, derived from 1298 published preclinical studies curated to AlzPED. **Inset:** Pie chart shows percentage of single, dual, triple and multi target therapeutic agents tested.

FROM MOUSE TO MEDICINE: OPTIMIZING THE PREDICTIVE VALUE OF PRECLINICAL RESEARCH

Notably, numerous therapeutic agents demonstrate varying extents of anti-inflammatory, antioxidant, beta amyloid-reducing, neuroprotective and cognition enhancing properties and are categorized as multi target therapeutics. Agents that have multiple documented targets are also categorized as multi target therapeutics. The database also describes several therapeutic agents that have dual or triple target specificities (Figure 10, inset). Examples of dual/triple specificity therapeutic agents include dual or triple receptor agonists or antagonists, metal chelators and ionophores.

Currently, AlzPED stores information on 251 therapeutic targets that aim to reduce beta amyloid and tau-related pathology and address disease-associated inflammation, oxidative stress, metabolic, synaptic, and behavioral dysfunction. These assorted targets are categorized into amyloidogenic proteins, tau protein, non-amyloid proteins, enzymes, channels, receptors and transporters, metal ions, and free radicals (Figure 11).




AlzPED also includes 23 therapeutic targets (Table 2) from a list of more than [500 nascent drug targets](#) that have been nominated by researchers from the NIA's [Accelerating Medicines Partnership in Alzheimer's Disease \(AMP-AD\) Consortium](#).

Therapeutic Target	Gene
alpha Synuclein	SNCA
Angiotensin I Converting Enzyme (ACE)	ACE
Apolipoprotein E (ApoE)/Apolipoprotein E4 (ApoE4)	APOE
CD33	CD33/SIGLEC3
Colony Stimulating Factor 1 Receptor (CSF1R)	CSF1R/CSFR
Corticotropin-Releasing Factor Receptor 1 (CRFR1)	CRHR1/CRFR/CRF1/CRFR1
Excitatory Amino Acid Transporter 2 (EAAT2)	SLC1A2/EAAT2
Extracellular Signal-Regulated Kinase 2 (ERK2)	ERK2/MAPK1
Glucocorticoid Receptors	NR3C1
Glycoprotein 130/Interleukin 6 Signal Transducer (gp130/IL6ST)	GP130/IL6ST
Histone Deacetylase 1 (HDAC1)	HDAC1
Insulin Receptor	INSR
Insulin-Like Growth Factor 1 Receptor (IGF1R)	IGF1R
Myelin Oligodendrocyte Glycoprotein (MOG)	MOG
Myelin Proteolipid Protein (PLP)	PLP1
Peroxisome Proliferator-Activated Receptor alpha (PPAR alpha)	PPARA
Programmed Cell Death Protein 1 (PD-1)	PDCD1/PD1
Retinoid X Receptor alpha (RXR alpha)	RXRA
Signal Transducer and Activator of Transcription 3 (STAT3)	STAT3
Specificity Protein 1 (Sp1)	SP1
Sphingosine-1-Phosphate Receptor	S1PR1
Triggering Receptor Expressed on Myeloid Cell 2 (TREM2)	TREM2
Tumor Necrosis Factor Receptor-I (TNF-RI)	TNFRSF1A

Table 2: The table lists the diverse therapeutic targets catalogued in AlzPED that have been nominated by researchers from NIA’s AMP-AD Consortium.

Animal Models

Within the 1298 curated studies compiled in AlzPED, 6 different animal species have been utilized, a majority of which are mouse models of AD (Figure 12). Other animal species include rat, guinea pig, rabbit, dog, and non-human primate models of AD. Preclinical efficacy data from 51 model types and 210 different AD animal models are currently available in AlzPED. Also included are data from 26 mouse models of ADRD (including tauopathies and synucleinopathies). Preclinical efficacy data from new AD animal models generated in the NIA-established [Model Organism Development and Evaluation for Late-Onset Alzheimer’s Disease \(MODEL-AD\) Consortium](#) will be included as they become available.




Outcome Measures

Each curated study provides an individual snapshot of the measures tested and outcomes achieved in response to the therapeutic agent tested. AlzPED defines 22 major outcome measures that are categorized as either functional or descriptive (Figure 13).

Functional measures include behavioral, motor, electrophysiological and imaging outcomes. Of these functional measures, behavioral outcomes are most commonly tested. There are 90 unique behavioral outcomes measured, from which the Morris water maze, novel object recognition, open field tests and Y maze are the most frequently studied. Within the 26 different motor function outcomes measured, locomotor activity, swimming speed, path length and the rotarod test are the most frequently studied. 74 diverse electrophysiological outcomes are measured, the most frequently measured being long term potentiation, field excitatory postsynaptic potentials, paired pulse facilitation and input/output (I/O) curve. Within the 51 unique imaging outcomes measured, cerebral blood flow, structural MRI and *in vivo* two-photon amyloid and calcium imaging are the most frequently studied.

FROM MOUSE TO MEDICINE: OPTIMIZING THE PREDICTIVE VALUE OF PRECLINICAL RESEARCH



Descriptive measures include ADME, biochemical, biomarker, cell biology, chemistry, electron microscopy, histopathological, immunochemical, immunological, microscopy, omics (proteomics, lipidomics, metabolomics, transcriptomics, and others), pharmacodynamic, pharmacokinetic, pharmacological, physiological, protein structures, spectroscopy, and toxicology outcomes.

Within the descriptive measures tested, beta amyloid pathology-related biochemical, histopathological, immunochemical, and biomarker outcomes are a major focus in the studies curated to AlzPED. These measures analyze several species of beta amyloid including soluble, insoluble, monomers, oligomers, fibrils, and plaques. Other measures in these categories include evaluation of several species of tau (soluble, insoluble, aggregated, hyperphosphorylated, and others), as well as astrocytic, microglial, and synaptic markers.

Notably, even though beta amyloid, tau species, and glial markers are a major focus, an extraordinary range of factors and molecules are investigated within these 4 descriptive measures. In total, information from 1476 biochemical, 39 histopathological, and 439 immunochemical measures are currently available in AlzPED. As many as 40 different biomarkers have been analyzed, and beta amyloid markers in plasma, serum, or CSF constitute a large proportion.

FROM MOUSE TO MEDICINE: OPTIMIZING THE PREDICTIVE VALUE OF PRECLINICAL RESEARCH

Other frequently studied descriptive measures used to characterize the therapeutic agent being tested include ADME, pharmacokinetic, pharmacodynamic and toxicology outcomes. Of the 26 ADME measures studied, the most commonly tested are biodistribution, metabolic stability, and cytochrome p450 inhibition capability of the therapeutic agent. Similarly, 113 different pharmacodynamic measures are examined with key focus on reducing beta amyloid species. As many as 60 pharmacokinetic measures have been analyzed, with drug concentration in brain and plasma being evaluated most frequently. A comprehensive listing of at least 111 toxicology measures such as Ames tests, enzyme profiles, organ histology, and others are available in the database as well. Of these, the most frequently evaluated are body weight, general behavior, and food and water intake.

AlzPED reports on 18 different physiological measures from which blood pressure and cerebral blood flow are most frequently evaluated, as well as 8 pharmacological measures from which the most commonly tested are binding affinity and target selectivity of the therapeutic agent. As many as 111 cell biology outcomes are measured, of which cell viability and cytotoxicity are the most common measures. Of the 36 immunological measures reported, antibody titers and target specificity are most frequently evaluated. AlzPED also informs on 33 OMICS-related measures such as metabolomics and gene expression profiles, 37 electron microscopy outcomes, 69 microscopy outcomes and 20 spectroscopy outcomes. Finally, AlzPED also reports on protein structure and chemistry outcomes. In summary, there are more than 2500 AD-related outcomes measured in 1298 preclinical studies curated in this database.

SUMMARY

Human clinical trial designs are based on results from late-stage preclinical animal research. The success of these trials depend on the quality of the preclinical research, so there is a high cost when animal research fails to be reliable or reproducible. Poorly designed preclinical studies can lead to mistaken results that slow the progress of science, lead the scientific community astray, waste valuable resources, waste animal life, and lead to high rates of failure in the development of novel therapeutics. This is especially true for AD therapy development. Thus far, there are [very few drugs approved by the FDA](#) and these have a mild impact on symptoms in a subset of patients, have no effect on disease progression and mortality, and may produce serious adverse effects.

Rigorous experimental design and transparent reporting are clearly essential if animal studies are to inform future research, science policies, and successful clinical trials. AlzPED prioritizes and promotes the use of rigorous methodology in the planning of animal studies through its Rigor Report Card. The Rigor Report Card, through its checklist of experimental design elements, creates awareness of reporting recommendations and standards early in the research process and provides a practical and easy approach to planning a therapeutic study in animals. It also provides a starting point to evaluate the quality of reporting practices as well as assess the effectiveness of policies and interventions intended to improve the reporting of animal experiments and their predictive validity.

Ultimately, rigorous science and its comprehensive and transparent reporting are our responsibility – in how we design, execute, and report experiments, in how we conduct peer review of grants and papers, and in how we teach the next generation of scientists about rigor, reproducibility, and transparent reporting of research. Raising the bar for preclinical studies will require a concerted effort from the scientific community, funding agencies, and scientific journal publishers, so that funded and published research are sufficiently rigorous, transparent, and reproducible.